Skip to content

Visualmed

Clinical trials summarized as Visual Abstracts

Menu
  • Submit Article
  • About
  • Private Policy
  • Visualmed App for iphone
  • Visualmed App for Android
  • List of Clinical Trials
Posted onDecember 14, 2020December 14, 2020Infectious Disease

WHO Solidarity Trial: Repurposed Antiviral Drugs for Covid-19

by admin

Name of the Trial WHO Solidarity Trial Title of the Trial Repurposed Antiviral Drugs for Covid-19 Design Open-label, randomized controlled trial Year of Publication 2020…

Read More
Posted onDecember 12, 2020December 12, 2020Infectious Disease

PlasmAr Trial: Convalescent Plasma in Covid-19 Severe Pneumonia

by admin

Title of the Trial PlasmAr: Convalescent Plasma in Covid-19 Severe Pneumonia Year of Publication 2020 Objective To assess if in patients with severe SARS-CoV-2 pneumonia,…

Read More
Posted onNovember 30, 2020December 13, 2020Pulmonary/Critical Care

HIGH-WEAN Trial: Extubation to High-Flow Nasal Oxygen + Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone

by admin

Objective The goal of the HIGH-WEAN trial was to evaluate if high-flow nasal oxygen with noninvasive ventilation, compared with high-flow nasal oxygen alone, decreased the…

Read More
Posted onNovember 16, 2020December 13, 2020Nephrology

Hyponatremia: Diagnostic Evaluation Visualized

by admin

Hyponatremia diagnosis can be challenging as serum sodium concentration is affected by wide variety of variables. In order to understand the concept of hyponatremia, we…

Read More
Posted onOctober 23, 2020October 23, 2020Infectious Disease

Tocilizumab in hospitalized patients with COVID-19

by admin

Tocilizumab is an antiinflammatory monoclonal antibody that was initially developed for rheumatoid arthritis. Based on its antiinflammatory mecahnism of action, it was hypothesized to have…

Read More
Posted onSeptember 27, 2020October 22, 2020Cardiovascular Disease

VERTIS CV Trial: Ertugliflozin Effect on CV Outcomes in Type 2 Diabetes

by admin

VERTIS CV Trial: The SGLT-2 inhibitors are the next generation drugs for type 2 diabetes as well as patients with heart failure. We have seen…

Read More
Posted onSeptember 11, 2020November 9, 2020Cardiovascular Disease

EMPEROR Reduced Trial: Empagliflozin in HFrEF

by admin

The SGLT-2 inhibitors were initially developed for diabetes but eventually noted to have significant effects on outcomes in patients with heart failure in addition to…

Read More
Posted onSeptember 4, 2020October 22, 2020Cardiovascular Disease

REALITY Trial: Transfusion in Patients With Myocardial Infarction and Anemia

by admin

Multiple small trials in the past have shown benefits of liberal transfusion strategy in patients having active MI. However, a large size trial was lacking.…

Read More
Posted onSeptember 2, 2020November 13, 2020Cardiovascular Disease

EAST AFNET 4 Trial: Early Rhythm control in Atrial Fibrillation

by admin

In patients with nonvalvular afib, rate control was considered to be no different than rhythm control based on the AFFIRM trial results that was published…

Read More
Posted onSeptember 1, 2020October 23, 2020Cardiovascular Disease

EXPLORER-HCM Trial: Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

by admin

EXPLORER HCM Trial Summary: Mavacamten is a novel cardiac-specific myosin ATPase inhibitor. It specifically reduces excessive cross-bridging with actin, which is associated with pathological hypercontractility…

Read More

Posts navigation

Page 1 Page 2 … Page 45 Next Page

Subscribe via Email

Select list(s)*

 

Loading
Amphibious Theme by TemplatePocket ⋅ Powered by WordPress